Search Results

You are looking at 1 - 10 of 255 items for :

  • "neutropenia" x
Clear All
Full access

Gary H. Lyman and Marek S. Poniewierski

Neutropenia and its complications represent the major dose-limiting toxicities associated with systemic cancer chemotherapy and is associated with considerable morbidity, mortality, and cost. 1 Neutropenic events may result in dose reductions or

Full access

Abiy Agiro, Andrea DeVries, Jennifer Malin and Michael J. Fisch

Factors recommend febrile neutropenia (FN) prophylaxis using a colony-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%). 7 CSF prophylaxis may also be considered based on patient risk factors

Full access

Brahm H. Segal and Alison G. Freifeld

-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP

Full access

Michaela A. Dinan, Bradford R. Hirsch and Gary H. Lyman

the future by more sophisticated personalization of care and more selective administration of interventions to those who stand to benefit most. Use Case: Colony-Stimulating Factors for the Prevention of Febrile Neutropenia Febrile neutropenia

Full access

Jeffrey Crawford and George M. Rodgers

Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford and Gary H. Lyman

R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 11 Trillet-Lenoir V Green J Manegold C

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt and Michael K. Wong

: reporting practices from randomized clinical trials . J Natl Compr Canc Netw 2003 ; 1 : 440 – 454 . 2 Dale DC . Colony-stimulating factors for the management of neutropenia in cancer patients . Drugs 2002 ; 62 ( Suppl 1 ): 1 – 15 . 3

Full access

Thomas A. Cumbo and Brahm H. Segal

Elser C . Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation . Ann Hematol 1998 ; 77 : 41 - 45 . 10 Bjerke JW Meyers JD

Full access

David da Silva Dias, Catarina Jorge, Mafalda Baptista, Ana Júlia Arede, Paulo Luz, Tânia Madureira and Beatriz Gosalbez

Introduction: Febrile neutropenia (FN) induced by chemotherapy (ChT) arises until 6 weeks after the last cycle, usually between 5 and 10 days post-ChT. Infection risk is 20%–30%. It is difficult to stratify patients with low risk of complications

Full access

Anna M. Gibson and Claire Sutherby

Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in